This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Kidney and Renal Pelvic Cancer
  • /
  • Cabozantinib: an Active Novel Multikinase Inhibito...
Journal

Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma.

Read time: 1 mins
Published:28th Feb 2017
Author: Tannir NM, Schwab G, Grünwald V.
Availability: Free full text
Ref.:Tannir NM, Schwab G, Gr´┐Żnwald V.
DOI:10.1007/s11912-017-0566-9

Clear cell renal cell carcinoma (RCC) is characterized by inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene. VHL loss drives tumor angiogenesis and accounts for the clinical activity of VEGF receptor (VEGFR) tyrosine kinase inhibitors (TKIs), the first-line standard of care for advanced RCC. Within the last year, three new second-line treatments have received FDA approval for use after anti-angiogenic therapy: the immune checkpoint inhibitor nivolumab, the TKI cabozantinib, and the combination of the TKI lenvatinib and the mTOR inhibitor everolimus.

Cabozantinib inhibits VEGFRs, MET, and AXL, kinases that promote tumorigenesis, angiogenesis, metastasis, and drug resistance. Compared with everolimus, cabozantinib has shown statistically significant improvements in the three key efficacy endpoints of overall survival, progression-free survival, and objective response rate in patients with RCC who were previously treated with a VEGFR TKI. Herein, we summarize the translational research and clinical development that led to approval of cabozantinib as second-line therapy in RCC.

 

Read abstract on library site

Access full article